Accelerating the Industrialization of Synthetic Biology: A New Turning Point for Biomanufacturing in 2026
Editor
The Turning Point in the Commercialization of Synthetic Biology
In January 2026, industry-wide analyses suggest that the global synthetic biology sector has moved beyond the laboratory phase and entered a full-fledged commercialization trajectory. According to the latest report by McKinsey & Company, the synthetic biology market grew from $32.8 billion in 2025 to $42 billion in 2026, a 28% increase, surpassing previous forecasts by 15%. Notably, 67% of the total market growth was driven by actual commercialization revenues rather than research and development investments. This shift signifies that synthetic biology is no longer a future technology but a core driver of current industry dynamics.
Ginkgo Bioworks, based in Boston, USA, is considered a symbolic company of this transition. In its Q4 2025 earnings report, the company announced revenues of $230 million, a 156% increase compared to the same period the previous year. More significant is the change in revenue composition. While R&D service revenues accounted for 78% of total revenue until 2024, this decreased to 52%, whereas revenues related to actual biomanufacturing and production surged to 48%. This is a clear indicator that synthetic biology companies are transitioning their business models from research-centric to production-centric.
Korean biomanufacturers are also actively aligning with this global trend. Samsung Biologics, headquartered in Songdo, Incheon, completed a dedicated synthetic biology-based biopharmaceutical production line by the end of 2025, expanding its annual production capacity from 360,000 liters to 520,000 liters. A company representative stated, “Biopharmaceutical production using synthetic biology reduces production time by 40% and improves yield by 25% compared to traditional methods.” Consequently, Samsung Biologics’ order backlog for Q1 2026 increased by 89% year-on-year to $4.7 billion.
Celltrion is also accelerating its investment in the field of synthetic biology. The company, headquartered in Yeonsu-gu, Incheon, announced that it began full-scale development of synthetic biology-based biosimilars in the second half of 2025 and plans to invest a total of 800 billion won over the next three years. Notably, Celltrion is diversifying its portfolio from its existing focus on antibody biosimilars to developing new therapeutics using synthetic biology. This strategic shift reflects the rapidly increasing importance of synthetic biology in the global biopharmaceutical market.
Achieving Technological Innovation and Cost Efficiency Simultaneously
The key factor driving the commercial success of synthetic biology is the simultaneous achievement of technological innovation and economic efficiency. According to a January 2026 study in the journal Nature Biotechnology, biomanufacturing processes using synthetic biology reduce production costs by an average of 35% compared to traditional chemical synthesis methods. More importantly, production time is significantly reduced. Complex compound production, which previously took 6-8 months, is shortened to 2-3 months through synthetic biology, dramatically improving market responsiveness.
The case of Zymergen, based in Emeryville, California (now acquired by Ginkgo Bioworks), specifically demonstrates this efficiency improvement. The company’s synthetic biology-based industrial enzyme production platform improved productivity by 312% compared to traditional methods. Specifically, enzyme production per liter increased from 2.3 grams to 9.5 grams, and production costs decreased by 63% from $847 per kilogram to $312. This dramatic improvement shows that synthetic biology is becoming a key element of industrial competitiveness beyond mere technological innovation.
Hanmi Pharmaceutical in Korea is achieving notable success in new drug development using synthetic biology. The company, headquartered in Songpa-gu, Seoul, successfully completed preclinical trials for three synthetic biology-based anticancer drug candidates in 2025, announcing that two of these candidates have complex structures that cannot be produced through traditional chemical synthesis. Particularly, the candidate named HM-2847 has a unique three-dimensional structure producible only through synthetic biology, showing 4.7 times improved selectivity compared to existing anticancer drugs. Consequently, Hanmi Pharmaceutical’s R&D investment for 2026 is expected to increase by 23% year-on-year to 234 billion won.
The adoption of synthetic biology in the global pharmaceutical industry is also accelerating. Biogen, based in Cambridge, Massachusetts, announced the establishment of a dedicated synthetic biology research center by the end of 2025 and plans to invest $1.2 billion over the next five years. The company is particularly focusing on developing complex protein therapeutics for Alzheimer’s treatment using synthetic biology, which are difficult to produce with traditional methods. Gilead Sciences, based in Foster City, California, also demonstrated active interest in this field by investing a total of $470 million in three synthetic biology startups in 2025.
As a result of these large-scale investments and technological innovations, the market entry of synthetic biology-based products is becoming more pronounced. As of January 2026, the number of synthetic biology-based pharmaceuticals approved by the U.S. FDA has increased by 92% from 12 in 2024 to 23. The European Medicines Agency (EMA) also approved 18 products, a 125% increase year-on-year. This indicates that regulatory authorities are beginning to recognize the safety and efficacy of synthetic biology technologies, and the pace of commercialization is expected to accelerate further.
Market analysts assess that the combination of technological maturity and economic efficiency signifies the entry of the synthetic biology industry into a full-fledged growth phase. Goldman Sachs’ biotech analysis team forecasts that “2026 will be the ’tilting point’ for the synthetic biology industry,” predicting that “as technological innovation and commercial feasibility are simultaneously demonstrated, large-scale capital inflow and market expansion will become full-fledged.”
Global Competitive Landscape and Investment Trends
As global competition in the field of synthetic biology intensifies, the scale of investment by governments and companies is rapidly expanding. In 2025, global venture capital investment in synthetic biology totaled $8.7 billion, a 34% increase from the previous year, with 67% concentrated on companies in the commercialization stage. Notably, the proportion of investment in early-stage R&D has decreased, while investment in companies with actual production and commercialization capabilities has surged. This change in investment patterns clearly shows that the focus of the synthetic biology industry is shifting from research to commercialization.
The United States continues to play a leading role in the field of synthetic biology. In 2025, the number of synthetic biology-related patent applications in the U.S. was 4,267, an 18% increase from the previous year, accounting for 41% of global patent applications. The patent portfolios of major U.S. companies such as Ginkgo Bioworks, Synthetic Genomics, and Twist Bioscience are continuously expanding. Ginkgo Bioworks, for example, filed 327 new patents in 2025 alone, the largest number in a single year since the company’s founding. This competition to secure intellectual property rights is recognized as a key strategy for securing future market dominance.
China is also rapidly catching up in the field of synthetic biology. The Chinese government announced a ‘Five-Year Plan for the Development of Synthetic Biology’ in 2025, pledging to invest a total of $20 billion by 2030. Synthetic biology industry clusters are being established, focusing on Beijing, Shanghai, and Shenzhen, with existing biotech companies like BGI Genomics and WuXi Biologics expanding their synthetic biology business areas. China’s synthetic biology market size is expected to grow from $3.2 billion in 2025 to $4.5 billion in 2026, significantly exceeding the global average growth rate.
The European Union is also expanding support for synthetic biology research through the ‘Horizon Europe’ program. In 2025, the EU provided a total of €1.5 billion for synthetic biology-related research projects, which is expected to increase to €1.9 billion in 2026. European companies such as Evonik Industries in Germany, DSM in the Netherlands, and Novartis in Switzerland are also accelerating their investments in the field of synthetic biology. Notably, Evonik completed a dedicated synthetic biology production facility in Essen, Germany, in 2025, with an annual production capacity of 20,000 tons, the largest in Europe.
The Korean government is also recognizing synthetic biology as a next-generation growth engine and is expanding policy support. The Ministry of Science and ICT announced a ‘Synthetic Biology Technology Development and Commercialization Support Plan’ in 2025, pledging to invest a total of 1.2 trillion won by 2030. Of this, 60% will be allocated to support commercialization by companies, and 40% will be invested in basic research. Additionally, specialized industrial complexes for synthetic biology are being established in Pangyo, Daedeok, and Osong to promote the clustering of related companies. With this government support, Korea’s synthetic biology market is expected to grow from $800 million in 2025 to $1.2 billion in 2026, a 50% increase.
Investments in the field of synthetic biology by venture capital and private equity firms are also significantly increasing. In 2025, the world’s largest dedicated synthetic biology fund, ‘Synthetic Biology Fund III,’ was established with a scale of $2.7 billion, an 80% increase compared to the previous fund. Additionally, mergers and acquisitions by existing pharmaceutical and chemical companies are becoming more active. In 2025, there were a total of 23 M&A transactions in the field of synthetic biology, with a transaction volume of $15.6 billion, representing increases of 35% and 67% year-on-year, respectively. This active investment and M&A activity indicates the increasing maturity of the synthetic biology industry.
In the global competitive landscape, a notable point is that specialization strategies by technology field are becoming more distinct. U.S. companies are strong in platform technology and software, European companies are focusing on sustainable chemical material production, China is showing competitiveness in mass production and commercialization capabilities, and Korea is securing a unique position in the biopharmaceutical manufacturing field. These regional specialization strategies are expected to form a division of labor structure in the future global synthetic biology ecosystem, with cooperation and competition among companies from different countries expected to expand simultaneously.
Industry experts evaluate that 2026 will be a crucial year in determining the global competitive landscape of the synthetic biology industry. Based on the investments and technological development achievements so far, market dominance is likely to be determined over the next 5-10 years, and as a result, investment competition among governments and companies is expected to become more intense. Securing intellectual property rights in key technology fields and building commercialization capabilities are analyzed to be the core elements of competition.
In summary, the state of the synthetic biology industry in 2026 can be evaluated as having entered a full-fledged industrialization phase, with technological maturity and commercial feasibility simultaneously demonstrated. Particularly, the reduction in production costs and efficiency improvements have been proven with concrete figures, accelerating the paradigm shift in traditional chemical and pharmaceutical industries. Amidst intense global competition, large-scale investments by governments and companies are continuing, forecasting explosive growth in the synthetic biology market in the coming years. Korean companies must actively seek new opportunities in the era of synthetic biology, leveraging their existing competitiveness in the biomanufacturing field.
*The content of this article is for informational purposes only and is not intended as investment solicitation or advice. Investment decisions should be made at the individual’s discretion and responsibility.*
